Drugs / Flurbiprofen
Flurbiprofen
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | OCUFEN | — | 1986-12-31 | fda.gov ↗ |
Trials 48
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05955885 | Jul 2023 → Jul 2024 | respiratory tract infectious disorder | University of Melbourne | Completed | No outcome recorded |
| Phase 126 trials | ||||||
| Phase 1 | NCT07426042 | Apr → May 2026 overdue | — | Min Kyu Park | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07223671 | Dec 2025 → Feb 2026 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT07259330 | Oct 2025 → Mar 2026 | — | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 1 | NCT07235748 | Oct → Dec 2025 | — | Servier | Completed | No outcome recorded |
| Phase 1 | NCT06823284 | Jan → Feb 2025 | — | Teikoku Seiyaku Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05932277 | Jun → Sep 2023 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT05852769 | May → Aug 2023 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT05981365 | Apr → Oct 2023 | sickle cell disease | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT05254548 | Feb → Apr 2022 | — | Idorsia Pharmaceuticals Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05512013 | Feb 2022 → Apr 2023 | bone resorption disease, disease of bone structure | United States Army Research Institute of Environmental Medicine | Completed | No outcome recorded |
| Phase 1 | NCT04814498 | May → Sep 2021 | — | Blade Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT04425902 | Dec 2020 → Mar 2021 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 1 | NCT04643249 | Nov → Dec 2020 | mitochondrial disease | Abliva AB | Completed | No outcome recorded |
| Phase 1 | NCT03720366 | Oct 2018 → Sep 2023 | acute myeloid leukemia | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT03131973 | May → Nov 2017 | rheumatoid arthritis | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02762123 | May → Aug 2016 | rheumatoid arthritis | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02578277 | Nov → Dec 2015 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 1 | NCT02456844 | May → Jul 2015 | rheumatoid arthritis | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02391688 | Nov 2014 → Apr 2015 | — | Jules Desmeules | Completed | No outcome recorded |
| Phase 1 | NCT02227173 | Sep → Nov 2014 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02045966 | Feb → Apr 2014 | hepatitis C virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT01731067 | Nov 2012 → May 2013 | — | Jules Desmeules | Completed | No outcome recorded |
| Phase 1 | NCT00964106 | Aug 2009 → Aug 2011 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00920088 | Jun → Nov 2009 | HIV infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00615212 | Jan → Feb 2008 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00443170 | Nov 2006 → ? | anemia | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01026714 | Nov 2009 → Aug 2010 | — | University Hospital, Geneva | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT01040286 | Aug 2009 → Jun 2010 | periodontitis | Dexcel Pharma Technologies Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT00425451 | Aug 2008 → Jan 2009 | periodontitis | Dexcel Pharma Technologies Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT00759330 | Oct 2007 → Jul 2008 | chronic pain syndrome | Teikoku Pharma USA, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00001724 | Nov 1997 → Nov 2001 | — | National Institute of Dental and Craniofacial Research (NIDCR) | Completed | No outcome recorded |
| Phase 32 trials · 2 met primary | ||||||
| Phase 3 | NCT01048866 | Nov 2009 → Mar 2011 | pharyngitis | Reckitt Benckiser Inc. | Completed | Met primary |
| Phase 3 | NCT01049334 | Nov 2009 → Mar 2011 | pharyngitis | Reckitt Benckiser Inc. | Completed | Met primary |
| Phase 45 trials | ||||||
| Phase 4 | NCT06238154 | Oct 2023 → Jan 2024 | mouth disorder | Yuzuncu Yil University | Completed | No outcome recorded |
| Phase 4 | NCT06041178 | Sep 2022 → May 2023 | chronic periodontitis | Beirut Arab University | Completed | No outcome recorded |
| Phase 4 | NCT03745599 | Nov 2017 → Sep 2018 | — | Near East University, Turkey | Completed | No outcome recorded |
| Phase 4 | NCT01998217 | Sep 2012 → Dec 2013 | pancreas disorder | Changhai Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00519246 | Feb → Dec 2007 | neuropathy, painful | Nanjing Medical University | Completed | No outcome recorded |
| Phase not applicable9 trials | ||||||
| — | NCT07370402 | Dec 2025 → Sep 2027 expected | herpes zoster | Beijing Tiantan Hospital | Recruiting | No outcome recorded |
| — | NCT07163429 | Sep 2025 → Dec 2026 expected | — | Kittitorn Supphapipat, MD | Active not recruiting | No outcome recorded |
| — | NCT07416136 | Apr → Aug 2025 | impacted teeth, multiple | Marmara University | Completed | No outcome recorded |
| — | NCT06531837 | Aug 2024 → Jan 2026 overdue | chronic pain syndrome | Beijing Tiantan Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06220175 | Mar → Aug 2024 | — | Carol Davila University of Medicine and Pharmacy | Completed | No outcome recorded |
| — | NCT03337945 | Apr 2018 → Jun 2021 | cirrhosis of liver | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| — | NCT02789527 | Nov 2015 → Apr 2017 | — | Estella S. Poloni | Completed | No outcome recorded |
| — | NCT02438072 | Dec 2014 → Dec 2015 | depressive disorder | University Hospital, Geneva | Unknown | No outcome recorded |
| — | NCT00162474 | Sep 2003 → Dec 2030 expected | — | Hadassah Medical Organization | Recruiting | No outcome recorded |
| Comparator or background therapy18 trials | ||||||
| Phase 0 | NCT03090009 Comparator | Apr 2017 → Apr 2019 | mucositis | Polak David | Unknown | No outcome recorded |
| Phase 0 | NCT03165929 Comparator | May 2016 → Feb 2017 | — | Gazi University | Completed | No outcome recorded |
| Phase 1 | NCT05742256 Background | Mar 2023 → Jul 2024 | — | Qianfoshan Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT04505787 Comparator | Jul → Sep 2020 | — | SocraTec R&D GmbH | Completed | No outcome recorded |
| Phase 2 | NCT07826806 Comparator | Sep 2026 → Dec 2027 expected | — | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT04708964 Comparator | Jan → Jun 2021 | — | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Unknown | No outcome recorded |
| Phase 4 | NCT07531147 Comparator | Apr → Sep 2026 overdue | pharyngitis | Izmir Katip Celebi University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT04602845 Background | Apr → Jun 2021 | — | Peking University | Completed | No outcome recorded |
| Phase 4 | NCT03171987 Comparator | Jun 2017 → Mar 2021 | — | Taipei Medical University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02569905 Comparator | Apr 2014 → Apr 2015 | — | Guangxi Medical University | Completed | No outcome recorded |
| Phase 4 | NCT02114463 Comparator | Mar 2014 → Aug 2016 | — | Guangzhou General Hospital of Guangzhou Military Command | Unknown | No outcome recorded |
| — | NCT06566794 Comparator | Aug 2024 → Jan 2025 | — | Helsinki University Central Hospital | Completed | No outcome recorded |
| — | NCT06000137 Background | Feb 2022 → Jan 2023 | — | Eye & ENT Hospital of Fudan University | Completed | No outcome recorded |
| — | NCT04976790 Comparator | Oct 2021 → Feb 2022 | — | Beijing University of Chinese Medicine | Unknown | No outcome recorded |
| — | NCT04507165 Comparator | Aug 2020 → Jul 2021 | — | Peking University People's Hospital | Unknown | Met primary |
| — | NCT02784041 Background | Sep 2016 → Dec 2017 | osteoarthritis, knee | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| — | NCT02674737 Comparator | Jan → May 2016 | postgastrectomy syndrome | Chinese Medical Association | Unknown | No outcome recorded |
| — | NCT02670954 Background | Oct → Dec 2015 | — | Chinese Medical Association | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 67 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | flurbiprofen | “We administered the Basel phenotyping cocktail (caffeine, efavirenz, flurbiprofen, omeprazole, metoprolol, midazolam) to patients with liver cirrhosis (n = 16 Child A, n = 15...” PMID 37328712 ↗ Jun 202365“Nirogacestat 100 mg BID will be administered orally from Day 1 through Day 17 and an oral dose of CYP cocktail (CYP2B6 [bupropion 20 mg], CYP2C8 [repaglinide 0.05 mg], CYP2C9...” NCT07259330 ↗ “A CYP probe cocktail composed of approved, commercially available drugs (caffeine, flurbiprofen, omeprazole, and midazolam) will be administered concomitantly as a single-dose...” NCT07426042 ↗ “Klorhex Plus topical spray containing chlorhexidine gluconate and flurbiprofen is applied to the surgical site immediately after impacted mandibular third molar extraction and...” NCT07416136 ↗ “Ten volunteers received an oral cocktail capsule containing low doses of the probes bupropion (CYP2B6), flurbiprofen (CYP2C9), omeprazole (CYP2C19), dextromethorphan (CYP2D6),...” PMID 24722393 ↗ Apr 2014 “that is Strepsils Intensive with honey and lemon which contains flurbiprofen 8.75mg before upper GI endoscopy plus xilocaine spray improves the satisfaction score of the...” NCT06220175 ↗ “The present clinical trial will be conducted to characterise maximum observed systemic exposure of the newly developed EFHP (Test) vs. "Froben 100 mg" (Reference, containing...” NCT04505787 ↗ “The mixture contains 30ml (300mg) ropivacaine, 0.5ml (5 mg) morphine, 2 ml (50 mg) flurbiprofen and 0.5 ml of 1:1000 epinephrine, and then is diluted with 0.9% normal saline to...” NCT02784041 ↗ “Effects of BMS-955176 on the Single-dose Pharmacokinetics of Probe Substrates (Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin)...” NCT02578277 ↗ “Cocktail = Caffeine 200 mg, Metoprolol 50 mg, Montelukast 10 mg, Flurbiprofen 50 mg, Omeprazole 40 mg, Midazolam 5 mg, Digoxin 0.25 mg, and Pravastatin 40 mg” NCT02045966 ↗ “The Geneva cocktail is composed of caffeine, bupropion, flurbiprofen, omeprazole, dextromethorphan, midazolam, and fexofenadine.” PMID 32851583 ↗ Nov 2020 |
| Known as | Ansaid | “This study will evaluate the effectiveness of the non-steroidal anti-inflammatory drug flurbiprofen (Ansaid® (Registered Trademark)) in relieving pain following oral surgery.” NCT00001724 ↗ |
| Known as | Flurbiprofen Axetil | “flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg” NCT02114463 ↗1“Flurbiprofen Axetil 50 mg i.v.” NCT00519246 ↗ |
| Known as | Flurbiprofen spray | “Flurbiprofen spray applied to the cuff of laryngeal mask airways or single-lumen tubes reduces POST severity.” NCT07163429 ↗ |
| Known as | Froben | “The present clinical trial will be conducted to characterise maximum observed systemic exposure of the newly developed EFHP (Test) vs. "Froben 100 mg" (Reference, containing...” NCT04505787 ↗ |
| Action | Inhibit | “flurbiprofen axetil (a cyclooxygenase inhibitor)” PMID 26547293 ↗ Nov 2015 |
| Modality | Small molecule | “a chiral NSAID of the 2-arylpropionic acid class” NCT03165929 ↗ |
| Route | Other | “directly into the extraction site” NCT00001724 ↗ |